Patients receiving fludarabine for blood cancers face a hidden risk. The amount of drug their bodies actually handle differs greatly from person to person. This review found that drug exposure can vary by up to 14.5-fold between different patients. Such huge differences mean some people get far less medicine than intended while others get too much.
The study looked at how the drug moves through the body. It found that low drug levels correlate directly with treatment failure and non-relapse mortality. When exposure is suboptimal, patients face worse outcomes. This pattern holds true across the group studied.
The review offers a framework for identifying biomarkers to guide personalized medicine approaches. Doctors can use these markers to optimize fludarabine therapy and treatment outcomes. However, the sample size was not reported and specific setting details were missing. Without these numbers, we cannot know exactly how many people were involved or where the data came from. The evidence remains incomplete without these details.